12,372 trials
Pain
Primary: Summed Pain Intensity Difference (SPID) Score Calculated Over the First 48 Hours (SPID48) After the First Dose of Study Drug on an 11-Point Numerical Pain Rating Scale…
Other Surgical Procedures
Primary: Number of Participants With Fiberoptic Use During Surgeries Requiring Lung Isolation — 42; 5 Participants — p=<0.0001
Smoking Cessation
Primary: Number of Participants That Completely Switched From Combustible Cigarettes to Halo G6 E-Cigarettes — 8 Participants
Hereditary Angioedema
Primary: Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAE) — 0 Participants
Thrombosis
Primary: Percentage of Participants With Any Thrombotic Event (Venous or Arterial and Symptomatic or Asymptomatic) — 8.3; 1.6; 8.8; 0 percentage of participants
Atopic Dermatitis
Primary: Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 — 13.3; 60.1; 72.9…
Vernal Keratoconjunctivitis
Primary: Average Penalties Adjusted Composite Efficacy Score (CFS) Score Over the 4 Months — 2.06; 1.93; 1.34 Penalties Adjusted CFS Score — p=0.007
Insomnia Disorder
Primary: Change From Baseline to Month 1 in Wake After Sleep Onset (WASO) (Sleep Maintenance) — -18.40; -28.98; -6.20 minutes — p=<0.0001
Major Depressive Disorder
Primary: Change From Baseline in Children's Depression Rating Scale- Revised (CDRS-R) — -21.3; -23.0; -23.1 score on a scale — p=0.2215
Pneumococcal Infections · Pneumococcal Vaccines
Primary: Percentage of Participants With Solicited Injection-Site Adverse Events (AEs) in V114 Versus Prevnar 13™ — 69.0; 69.2; 33.7; 38.5 Percentage of participants — p== 0.039
Paroxysmal Nocturnal Hemoglobinuria
Primary: Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP — 2.37; -1.47 Grams per deciliter (g/dL) — p=<0.0001
Insomnia Disorder
Primary: Change From Baseline to Month 1 in Wake After Sleep Onset (WASO) (Sleep Maintenance) — -15.31; -24.19; -12.57 minutes — p=0.0001
Breast Cancer
Primary: Percentage of Participants With Pathological Complete Response (pCR) in the PD-L1-Positive Population (IC 1/2/3) — 64.2; 72.5 Percentage of Participants — p=0.1846
Neovascular Age-Related Macular Degeneration
Primary: Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score at the Average of Week 36 and Week 40, as Assessed Using the ETDRS Visual Acuity Chart at a Starting…
Atrial Fibrillation
Primary: Number of Participants Who Experienced Net Adverse Clinical Events (Adjudicated Data) Based on ISTH Criteria in Participants Taking Edoxaban vs VKA — 170; 157…